![Michael Parks](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Parks currently works at Atossa Therapeutics, Inc., as Vice President-Investor & Public Relations from 2024.
Mr. Parks also formerly worked at Centocor Johnson & Johnson, as Vice President-Corporate Communications, Liquidia Corp., as Head-Corporate Communications & Public Affairs, and PAVmed, Inc., as Vice President-Investor Relations.
| Società | Posizione | Inizio |
|---|---|---|
| ATOSSA THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 20/08/2024 |
| Società | Posizione | Fine |
|---|---|---|
| PAVMED INC. | Contatto Relazioni con gli Investitori | - |
Centocor Johnson & Johnson | Public Communications Contact | - |
| LIQUIDIA CORPORATION | Public Communications Contact | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Atossa Therapeutics, Inc.
 Atossa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics and delivery methods for the treatment of breast cancer & other breast conditions | Health Technology |
PAVmed, Inc.
 PAVmed, Inc. Medical SpecialtiesHealth Technology Develops and commercializes medical devices | Health Technology |
Centocor Johnson & Johnson | |
Liquidia Corp.
 Liquidia Corp. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
